Eligo Bioscience Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Employees
  • 34
Employees
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $3.14M
Latest Deal Amount
  • Investors
  • 9

Eligo Bioscience General Information

Description

Developer of antibiotics intended to treat microbiome precision and bacteria-associated diseases. The company's antibiotics combine CRISPR/Cas system with engineered phage capsids, to develop antimicrobials that are used to eradicate resistant pathogens or virulent bacteria within the human microbiome, enabling clients to get next-generation antimicrobials to treat diseases caused by superbugs.

Contact Information

Website
Formerly Known As
PhageX
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 29 rue du Faubourg Saint-Jacques
  • 75014 Paris
  • France

Eligo Bioscience Timeline

2017201820192020
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Eligo Bioscience Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Grant 01-May-2019 $3.14M 000.00 Completed Generating Revenue
7. Early Stage VC (Series A) 26-Sep-2017 0000 000.00 Completed Generating Revenue
6. Grant 20-Sep-2016 00.000 Completed Generating Revenue
5. Early Stage VC (Series A) 04-Aug-2016 00.000 00.000 000.00 Completed Generating Revenue
4. Grant 09-Feb-2015 00000 Completed Generating Revenue
3. Grant 08-Jun-2014 00000 Completed Generating Revenue
2. Accelerator/Incubator Completed Generating Revenue
1. Accelerator/Incubator Completed Generating Revenue
To view Eligo Bioscience’s complete valuation and funding history, request access »

Eligo Bioscience Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
A 000,000 00.0 00.0 00 00.0 00.000
To view Eligo Bioscience’s complete cap table history, request access »

Eligo Bioscience Executive Team (6)

Name Title Board Seat Contact Info
Xavier Duportet Ph.D Co-Founder, Chief Executive Officer and Chairman
David Bikard Ph.D Co-Founder & Chief Scientific Officer and Board Member
Aurélie Grienenberger Ph.D Chief Business Officer
Timothy Lu Ph.D Co-Founder & Advisor
Luciano Marraffini Ph.D Co-Founder
You’re viewing 5 of 6 executive team members. Get the full list »

Eligo Bioscience Board Members (2)

Name Representing Role Since
Jean-Pierre Lehner Eligo Bioscience Board Member 000 0000
Sebastien Groyer Ph.D Seventure Partners Board Member 000 0000
To view Eligo Bioscience’s complete board members history, request access »

Eligo Bioscience Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Eligo Bioscience Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
European Commission Government 000 0000 000000 0
Bpifrance Sovereign Wealth Fund Minority 000 0000 000000 0
Khosla Ventures Venture Capital Minority 000 0000 000000 0
L'Agence Nationale de la Recherche Government 000 0000 000000 0
Seventure Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »